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Abstract: The human mitochondrial DNA (mtDNA) encodes 37 genes, including thirteen proteins
essential for the respiratory chain, and RNAs functioning in the mitochondrial translation apparatus.
The total number of mtDNA molecules per cell (mtDNA content) is variable between tissue types
and also between tumors and their normal counterparts. For breast cancer, tumors tend to be
depleted in their mtDNA content compared to adjacent normal mammary tissue. Various studies
have shown that primary breast tumors harbor somatic mtDNA variants. A decrease in mtDNA
content or the presence of somatic variants could indicate a reduced mitochondrial function within
breast cancer. In this explorative study we aimed to further understand genomic changes and
expression of the mitochondrial genome within breast cancer, by analyzing RNA sequencing data
of primary breast tumor specimens of 344 cases. We demonstrate that somatic variants detected
at the mtRNA level are representative for somatic variants in the mtDNA. Also, the number of
somatic variants within the mitochondrial transcriptome is not associated with mutational processes
impacting the nuclear genome, but is positively associated with age at diagnosis. Finally, we observe
that mitochondrial expression is related to ER status. We conclude that there is a large heterogeneity
in somatic mutations of the mitochondrial genome within primary breast tumors, and differences in
mitochondrial expression among breast cancer subtypes. The exact impact on metabolic differences
and clinical relevance deserves further study.
Keywords: primary breast cancer; mitochondrial RNA variants; mitochondrial expression;
clinicopathological markers
1. Introduction
Mitochondria are small organelles involved in multiple cellular processes. They are most
renowned for their role in energy production, since they contain their own circular genomic entity
encoding proteins essential for the respiratory chain and thereby for generating cellular ATP via
oxidative phosphorylation. The human mitochondrial DNA (mtDNA) is gene-dense consisting of
~16569 base pairs encoding 37 genes: thirteen proteins, and two rRNAs and twenty-two tRNAs
functioning in the mitochondrial translation apparatus. Polycistronic transcription of mtDNA is
initiated at the non-coding D-loop region, and the resultant precursor transcripts are processed by
excision of the tRNA genes (“tRNA punctuation model” [1]) generating individual mitochondrial
tRNA, rRNA and mRNA transcripts. The total number of mtDNA molecules per cell (mtDNA
content) is variable between tissue types, and interestingly also between tumors and their normal
counterparts [2]. For breast cancer specifically, tumors tend to have reduced mtDNA content compared
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to adjacent normal mammary tissue [2–10], and mtDNA content in breast tumors positively correlates
with the expression of mtDNA-encoded genes [11]. Decreased content and expression of mtDNA
could indicate a reduced mitochondrial oxidative phosphorylation function within breast cancer, in
line with the Warburg hypothesis [12] limiting energy production largely to glycolysis. Recently, we
have shown mtDNA content to be associated with breast cancer patient outcome [13,14], underlining
the clinical relevance of mitochondria in breast cancer.
Apart from mtDNA content, the significance of somatic mtDNA variants within (breast) cancer is
still subject to debate, where the whole spectrum of neutral accumulation, positive selection (advantage)
and negative selection (disadvantage) have been postulated. Various studies have shown that primary
breast tumors harbor somatic variants in their mtDNA [8,15,16], with approximately 70% of the
specimens containing at least one single nucleotide variant (SNV, range 1–7) and 10% containing at least
one small insertion/deletion (INDEL, range 0–3). However, these variants do not appear at particular
‘hot-spot’ positions on the mitochondrial genome, raising doubts about their clinical relevance.
To better understand nucleotide changes in and expression of the mitochondrial genome within
primary breast tumors, we investigated here transcriptomic sequencing data within the International
Cancer Genome Consortium (ICGC) [17] and explored how these findings correlate with clinical
parameters, providing more insight into the mitochondrial genome as potential biomarker and its
clinical relevance in breast cancer.
2. Results
We evaluated RNA sequencing data of 344 primary breast tumor specimens. After mapping of
sequencing reads against the human reference genome, median 15% (Interquartile range (IQR) 10–23%)
of the uniquely mapped reads were assigned to the mitochondrial contig, resulting in median 9889×
read depth (IQR 5333) of mtDNA.
2.1. Somatic Variants in mtRNA
Variant calling resulted in a total of 9063 single nucleotide variants (SNVs) on 1600 positions
and 84 small insertions or deletions (INDELs) on 38 positions of the mitochondrial genome within
the 344 cases (Figure 1). Since INDELs were only a minority, our focus was on the SNVs only. We
defined SNVs as somatically acquired tumor variants when not associated with the individual’s
haplotype (n = 7235 excluded, 80%) or with heteroplasmic allele frequency of ≤95% (n = 917 excluded,
10%). Also, we defined the variants at position 2617 (r.2617a>u and r.2617a>g, present in respectively
n = 340 and n = 101 cases) as not tumor-specific because (1) they have been described previously
as RNA-DNA differences in blood cells of non-cancer patients [18,19] and (2) we confirmed their
presence in a transcriptomic dataset of normal specimens of various tissue types including breast
tissue [20] (Supplementary Materials Table S1). After these exclusions, a total of 470 somatic variants
on 429 positions were identified.
Our dataset has overlapping cases (n = 165) with the dataset published by Ju et al. [15] concerning
somatic mitochondrial variants in tumor and matched normal specimens at the DNA level. This
allowed us to directly compare called variants between the two datasets (see also Appendix A) to
evaluate presence, classification and allele frequency of variants. Since variants at position 2617 are
known RNA-DNA differences (see above) and indeed not called in the DNA dataset, these were not
included in this comparison. A total of respectively 3997 and 4009 SNVs were called at the RNA
and DNA level within the primary tumor specimens of the 165 cases. The majority of the variants
were called at both the RNA and DNA level (n = 3889, respectively 97.3% and 97.0%), whereas a
small fraction was only called at either the RNA or the DNA level (respectively n = 108 (2.7%) and
n = 120 (3.0%) variants) (Figure 2). Of the variants detected at both the RNA and DNA level, only a
few (n = 10, 0.3%) had a discrepancy in classification as either ‘somatic’ or ‘germline’ (Figure 2). Also,
good consistency was observed in allele frequency at the RNA and DNA level (linear fit coefficient
of 0.92 for all variants and 0.96 for somatic tumor variants). From this we concluded that presence,
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classification and allele frequency of variants was consistent between the RNA and the DNA level (as
elaborated on in the Appendix A).
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Figure 1. Variants in the mitochondrial RNA of 344 primary breast tumor cases. Position on the 
mitochondrial genome (circle) and their variant allele frequency (increasing % from inner-to-outer) 
of all variants identified in the 344 cases. Somatic or germline origin in respectively closed black or 
open grey circles. Genes and their direction of transcription (arrows) in red (+strand) or blue 
(−strand). Note that variants on position 2617 (known RNA-DNA differences) are not shown. 
 
Figure 2. Classification of variants detected in the mitochondrial RNA and in the mitochondrial 
DNA of 165 primary breast tumor cases. Venn-diagram depicting classification of variants as either 
somatic (black) or germline (grey) at the RNA level and the DNA level. 
Figure 1. Variants in the mitochondrial RNA of 344 primary breast tumor cases. Position on the
mitochondrial genome (circle) and their variant allele frequency (increasing % from inner-to-outer)
of all variants identified in the 344 cases. Somatic or germline origin in respectively closed black or
open grey circles. Genes and their direction of transcription (arrows) in red (+strand) or blue (−strand).
Note that variants on position 2617 (known RNA-DNA differences) are not shown.
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Figure 2. Classification of variants detected in the mitochondrial RNA and in the mitochondrial DNA
of 165 primary breast tumor cases. Venn-diagram depicting classification of variants as either somatic
(black) or germline ( rey) at the RNA level and th DNA l vel.
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We then continued to further decipher the somatic mtRNA variants in our dataset (n = 470 in
n = 344 cases). The variant allele frequency of the somatic variants was distributed with a peak at
the lower and at the upper end of allele frequencies (Supplementary Materials Figure S1). There was
no correlation between the variant allele frequency and the percentage of invasive tumor cells in the
evaluated specimen (Spearman correlation coefficient rho = 0.03, p = 0.5). The detected somatic variants
were distributed along the entire mitochondrial genome (Figure 1), with 40 (8.5%) variants located in
the tRNA genes, 69 (14.7%) in rRNA genes, 85 (18.1%) in the D-loop, 1 (0.2%) in the non-coding regions,
and 275 (58.5%) in the mRNA genes of which 212 (77.1%) had a nonsynonymous effect on the coding
amino acid (Figure 3). However, relative to their genomic size (9.0% tRNA genes, 15.1% rRNA genes,
6.8% D-loop, 0.4% non-coding and 68.7% mRNA genes) more variants were present in the D-loop and
fewer in the mRNA genes (Fisher exact p < 0.001). Also in comparison to the germline variants (variants
that were associated with the haplogroup of that individual or with an allele frequency > 95%, n = 8152)
there was a difference in genomic distribution (Fisher’s exact p < 0.001) with fewer somatic variants in
the D-loop but more in the tRNA and mRNA genes, and an enrichment for somatic nonsynonymous
mRNA variants (Figure 3). The positions of somatic variants were much more conserved among
species compared to the germline variants (Mann-Whitney test p < 0.001), as measured by the fraction
of species that harbor the reference sequence at that position (Conservation Index of respectively
median (IQR) 0.93 (0.36) and 0.76 (0.69)). A total of 69 (15%) somatic variants were recurrent and
positioned on 28 mitochondrial positions. The majority of the somatic variants (95%) represented
the typical replication-coupled mtDNA substitution pattern with predominantly C > T and T > C
transitions as described previously [15,16,21] in a nucleotide context similar to the germline variants
(Figure 4). However, compared to the detected germline variants the ratio between C > T and T > C
variants is shifted (Fisher exact p < 0.001) with an increased number of C > T transitions among the
somatic variants (Figure 4).
In the entire cohort, there are 112 (33%) cases with 0 somatic variants, 97 (28%) with 1 somatic
variant, and 135 (39%) with more than 1 somatic variant (range 2 to 7). Of the cases with more than
1 somatic variant, 82 (61%) had a difference > 20% allele frequency between variants, indicative for
(sub-)clonality.
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Figure 3. Genomic distribution of mitochondrial RNA variants of 344 primary breast tumor cases. 
Genomic distribution is depicted for somatic (left) or germline (right) variants in either non-coding 
(purple), the D-loop (orange), tRNA (red), rRNA (blue) or mRNA (green) regions of the 
mitochondrial genome. The percentage of total is indicated at the top of the bars. The percentage of 
substitutions in the mRNA regions with either a synonymous or nonsynonymous effect is indicated 
within the mRNA bar (light green). Note that variants at position 2617 (known RNA-DNA 
differences) are not included. 
i i tri ti f it c rial ariants of 344 ri ary reast t or cases.
ti i
the D-loop (orange), tRNA (red), rRNA (blue) or mRNA (green) regions of the mitoch ndrial
gen me. The percentage of total is indicated at the top of the bars. The perc nt ge of substitutions in
the mRNA regions with either a synonymous or nonsy onymous effect is i dicated within the mRNA
bar (light green). Note that variants at position 2617 (known RNA-DNA differences) are not included.
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2.2. Somatic Mitochondrial Variants in Relation to Somatic Variants in the Nuclear Genome
Next, to gain more insight into the relation between the mutational processes shaping mtDNA
and nDNA, we associated the amount of somatic mtRNA variants with the number of somatic variants
induced by the known major mutational patterns shaping the nDNA. For this purpose, we obtained
for the overlapping cases (n = 268) the number of nDNA variants as published by Nik-Zainal et al. [17].
There was no statistically significant association between the number of somatic mtRNA variants and
the total number of somatic variants in the nuclear DNA (Spearman correlation coefficient rho = 0.01,
p = 0.8). Next, we combined per case the number of variants in nDNA associated with the mutational
processes as described by Nik-Zainal et al. [17]: age-related (signatures 1 and 5), APOBEC-related
(signatures 2 and 13) and homologous-recombination deficiency-related (signatures 3 and 8) processes.
No statistically significant associations were observed between the number of somatic mtRNA variants
and any of these three mutational processes (all Kruskal-Wallis p > 0.2). Note that only two samples
within the dataset contained variants associated with mismatch-repair deficiency (signatures 6, 20
and 26), and none of samples contained variants associated with the signatures of unknown etiology
(signatures 17, 18 and 30), as a consequence of which these specific subgroups could not be evaluated.
2.3. Mitochondrial Gene Expression
To estimate th expression and transcript processing of the mitochondrial genome for each case,
transcripts per million (TPM, log2-transformed) were calculated for the entire mtDNA and each
mitochondrial-encoded gene individually. Expression of the entire mtDNA—normalized against the
nuclear genome and thus evaluated as driven by mtDNA content and transcription rate—was high
and showed minor variability among the 344 cases (median 19.9210 TPM, IQR 0.0045). Within the 37
mitochondrial-encoded genes—normalized within the mitochondrial genome and thus evaluated as
driven by processing of the polycistronic transcripts—the levels for genes encoding tRNAs were lowest
(median 12.52 TPM, IQR 1.32), followed by mRNAs (median 15.37 TPM, IQR 0.31) and rRNAs (median
16.83 TPM, IQR 0.48). Most variability was observed in levels of tRNAs. Also, distinct correlation
clusters were observed between the expression levels of the genes encoding mRNAs, tRNAs and
rRNAs, where among genes a positive correlation was present per gene-type, but between different
gene-types a negative correlation was present (Figure 5). No correlation was observed between the
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number of mtRNA variants and expression of the entire mtDNA (Spearman correlation coefficient
rho = −0.02, p = 0.7).
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mitochondrial-encoded genes (text of tRNA genes in red, rRNA genes in blue, mRNA genes in
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2.4. Association with Clinicopathological Parameters
Lastly, we explored how these findings correlate with relevant clinical parameters. We analysed
the number of somatic mtRNA variants (grouped variable as 0 variants, 1 variant and >1 variant per
tumor, Table 1) and the expression of the entire mitochondrial contig (continuous variable, Table 1)
in relation to traditional clinicopathological variables including age at diagnosis (n = 291 cases),
tumor size (T-stage) (n = 216 cases), pathological grade (n = 282 cases), estrogen receptor (ER) status
(n = 291 cases) and progesterone receptor (PR) status (n = 288 cases). Due to the low numbers of
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patients with HER2-amplified (n = 2 cases) and presenting with metastases at primary diagnosis
(n = 3 cases), these clinicopathological variables were not evaluated. Age at diagnosis was statistically
significant associated with both the number of somatic mtRNA variants (Kruskal-Wallis p = 0.022) and
expression of the entire mtDNA (Spearman correlation coefficient rho = 0.11, p = 0.049), where a higher
age corresponded to more somatic mtRNA variants and higher expression of the entire mtDNA. Also,
a highly statistically significant association was observed between expression of the entire mtDNA
and hormone receptor status (as evaluated at the protein level), with increased mtDNA expression
in the ER-positive and in the PR-positive tumors (respectively Mann-Whitney U test p < 0.001 and
p = 0.006). In fact, also a significant correlation was observed between expression of the entire mtDNA
and RNA expression of ESR1 or PGR (respectively Spearman correlation coefficient rho = 0.19 p < 0.001
and rho = 0.17 p = 0.001, n = 344 and n = 342 cases).
Table 1. Association between number of somatic tumor mtRNA variants or expression of the entire
mtDNA and clinicopathological variables.





0 Variants 1 Variant >1 Variants Median (IQR) TPM
Age 0.022 a 0.049 d
56 (28–85) 291 (100%) 53 (17) 55 (23) 61 (24) 0.11 c
unknown 53
Tumor size 0.07 b 0.051 a
T1 ≤ 2 cm 76 (35.2%) 33.8% 25.0% 44.4% 19.9202 (0.0043)
T2 > 2–5 cm 109 (50.5%) 47.9% 64.1% 42.0% 19.9207 (0.0045)
T3 > 5 cm 31 (14.4%) 18.3% 10.9% 13.6% 19.9223 (0.0047)
unknown 128
Grade 0.4 b 0.1 a
I 24 (8.5%) 9.9% 12.2% 5.1% 19.9202 (0.0037)
II 111 (39.4%) 40.7% 35.1% 41.0% 19.9216 (0.0044)
III 147 (52.1%) 49.5% 52.7% 53.8% 19.9209 (0.0049)
unknown 62
ER 0.3 b <0.001 a
Negative 81 (27.8%) 21.7% 31.2% 30.3% 19.9196 (0.0050)
Positive 210 (72.2%) 78.3% 68.8% 69.7% 19.9216 (0.0041)
unknown 53
PR 0.5 b 0.006 a
Negative 102 (35.4%) 31.5% 40.5% 35.0% 19.9204 (0.0048)
Positive 186 (64.6%) 68.5% 59.5% 65.0% 19.9215 (0.0042)
unknown 56
For each subgroup within the clinicopathological variable, the number of cases and either the fraction of patients
within the mtRNA somatic variant groups (0, 1 or more than 1) or the mtRNA expression (TPM, log2 transformed)
is indicated. a Kruskal-Wallis (multiple groups) or Mann-Whitney (two groups) p-value. b Fisher exact p-value.
c Spearman correlation coefficient. d Spearman correlation p-value.
3. Discussion
In this work, we explored genomic changes in and expression of the mitochondrial genome within
primary breast tumors, and their correlation with clinicopathological variables.
Within our breast tumor dataset, the fraction of reads mapping to the mitochondrial contig of
the reference genome (median 15%) is in line with previous findings in non-tumorous breast samples:
within the Illumina Body Tissue Atlas ~15% of the sequencing reads mapped to the mitochondrial
genome (n = 1) [22], and within the Genotype-Tissue Expression (GTEx) Consortium ~15–20% of the
transcriptional output was of mitochondrial origin (n = 27) [23]. This is in line with the requirement for
functional mitochondria within cancer cells [24]. This also indicates that although the expression of the
mitochondrial genome has been shown to be decreased in breast tumors compared to tumor-adjacent
normal mammary tissue [11], the extent to which this occurs is less extreme than observed among
tissue types (e.g., a much lower fraction of mitochondrial reads in blood (<5%) or much higher fraction
in kidney (>50%) [23]). Nevertheless, we observed an association between expression of the entire
mtDNA and ER status (measured at protein-level), with marginally higher expression in ER-positive
tumors and a similar observation for PR status (protein-level) (Table 1). In addition, also RNA
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expression of ESR1 and PGR was positively correlated with expression of the entire mitochondrial
contig. The relation between expression of mtDNA and clinicopathological parameters has not
been evaluated by others, but when we associated the data reported by Reznik et al. [11] on mtRNA
expression within the TCGA-BRCA dataset (n = 656 cases) we observe a similar correlation for ER status
(Kruskal-Wallis p = 0.006, Supplementary Materials Table S2 and none for the other clinicopathological
variables (all p > 0.05 Supplementary Materials Table S2). In pre-clinical models, there appears to
be a link between ER and mitochondrial activity: exposure to estrogens increases mitochondrial
expression and oxygen consumption in ER-positive [25,26] but not in ER-negative breast cancer
cells [26]. Similarly, ER-negative breast cancer cell lines show lower mitochondrial respiration and a
stronger dependency on glycolysis in comparison to ER-positive breast cancer cells [27]. Unfortunately,
measurements on mitochondrial activity comparing ER-positive and ER-negative clinical specimens
are to our knowledge not reported in the literature, and thus the effect of differences in ESR1 levels on
mitochondrial activity in primary breast tumors remains currently unknown. Interestingly, uptake
values of fluorodeoxyglucose (FDG) in positron emission tomography (PET)—a visualization of
glucose uptake reflecting the increased rate of glycolysis in the tumor—appears to be higher in
ER-negative cases [28–34], indicative that indeed metabolic differences are present between the
subtypes. Additional studies should be performed to identify if there are differences in mitochondrial
(oxidative phosphorylation) function among breast cancer subtypes and the potential clinical relevance
of these findings, such as predictive and prognostic potential.
We also observed distinctive clustering of tRNA genes, which is in line with the tRNA punctuation
model: when processing the polycistronic transcripts, tRNA genes are excised and due their small size
(<75 base pairs) tRNAs are more likely to be lost during the RNA extraction and/or library preparation
procedures, whereas the mRNA and rRNA genes are retained (>200 base pairs). Notably, we did
not observe differences in this distinct pattern between the ER-positive and the ER-negative cases
(Supplementary Materials Figures S2 and S3), and thus the processing of the polycistronic transcripts
does not seem to differ between these two subtypes.
Our findings on the number, genomic distribution, and substitution pattern of mtDNA variants
within the mitochondrial transcriptome are in line with previous studies on variants within the
mitochondrial genome in other cancer types [8,15,16,21,35,36] (see also Appendix A). We observe
an increased number of somatic variants in the D-loop and fewer in mRNA genes than expected by
genomic size, which might be explained by the gene-dense constitution of mtDNA: variants in the
D-loop potentially have less destructive effects whereas variants in the mRNA genes might have
detrimental effects on the function of the oxidative phosphorylation system, and thus will be selected
against. Also, the structural conformation of the D-loop (a triple-stranded structure) could make
it more prone to damage. However, compared to germline variants in our dataset there are fewer
variants in the D-loop and more in the tRNA and mRNA genes, and enrichment for nonsynonymous
variants. This might be explained by the typical mutation pattern shaping mtDNA, which has been
shaping the germline variants and thus the trivial positions have already been altered, as suggested
by Ju et al. [15]. In line with this, the conservation of variants among species—the fraction of species
that harbor the reference sequence at that position—was much higher for somatic variants than for
the germline variants, which can be explained by the same hypothesis. Adding to this, compared to
the detected germline variants there is an increased number of C > T transitions among the somatic
variants (Figure 4). Note that the functional effect of somatic mtDNA variants on mitochondrial
function is dependent on the actual position (e.g., protein-coding regions) and consequence (e.g.,
stop-gain or nonsynonymous) of the variant in combination with their heteroplasmy level within
the tumor cell, rather than merely the number of somatic variants observed.Adjusting variant allele
frequency to account for sample purity (percentage of tumor cells within the specimen) is often applied
for nuclear-encoded genes to obtain information on the allele frequency of variants in the tumor cells.
However, this is not possible for mtDNA variants in tumor tissue specimens: the number of mtDNA
molecules per cell largely varies among cell types and thus the non-tumor cells present in the specimen
Cancers 2018, 10, 500 9 of 26
do not have the regular two copies as the nuclear genome would have, but contain multiple mtDNA
copies of an unknown number. As a result, whereas allele frequency of variants could give information
on possible constraints on variants, we did not perform analysis on it since it is impossible to estimate
the actual allele frequency of variants in the mitochondria of tumor cells. Nevertheless, we show
that majority of the samples with more than 1 somatic variant harbor a difference in variant allele
frequency between variants, indicative for (sub-)clonality. This corresponds to the hypothesis that
mtDNA variants are either expanded or lost [37] and that the mutations occur separated in time [15].
Also noteworthy is that with the current methodologies applied by us and by others—namely
the use of non-micro dissected tumor specimens and blood as matched normal DNA—we cannot be
completely sure that the detected somatic mtDNA mutations are tumor-specific. First, tumor tissue
specimens consist of multiple cell types, including the tumor cells but also non-neoplastic cells such as
immune cells and cells from the mammary epithelium, all with variable mtDNA content. Secondly,
(somatic) mtDNA variant heteroplasmy patterns can differ within an individual across tissues [38–41].
Thus, the somatic variants were either acquired in the tumor, the normal somatic epithelium, or even
in other cell types present within the specimen.
We did not observe associations between the number of somatic mtRNA variants and the three
major mutational processes shaping the nDNA within breast tumors. This is in line with the hypothesis
that mutations within the mitochondrial genome are mainly due to fidelity of the mitochondrial
polymerase [42] and thereby hardly due to exogenous factors [15]. Accordingly, in our evaluation of
associations with clinicopathological parameters we observed a statistically significant association
between the number of mtRNA somatic variants and age at diagnosis. Previous work on somatic
variants at the DNA level also revealed a correlation with older age of diagnosis (n = 381 [15] and n = 58
cases [35]). Previous work in a small cohort also showed associations between number of somatic
variants in mtDNA and higher TNM and higher histological grade (n = 58 cases [35]), which we did not
observe. Please note that there are differences in the composition of the cohorts; our dataset does not
exactly represent the breast cancer population as seen in daily practice, with an underrepresentation of
ERBB2-amplified cases (Supplementary Materials Table S3).
By using data at the RNA level, we intended to minimize the interference of NUMTs with
evaluation of mtDNA expression and variant calling, since their expression in the nucleus is negligibly
low [11,43]. Especially in defining heteroplasmic mtDNA variants in DNA data, NUMTs have
been shown to be a complicating issue with non-identical positions misinterpreted as heteroplasmic
variants [44–48]. Note that we do observe a few heteroplasmic variants at the DNA-only level
(Appendix A). However, using data at the RNA level comes with the trade-off that only variants in
expressed regions are detected and thus variants in non-expressed regions are missed. Since mtDNA
is a gene-dense entity, we estimate that the number of missed variants should be low. Indeed, in our
direct comparison of samples with variants at the RNA and DNA level, we show that this is maximally
~3% of the variants (DNA-only variants). Similar to these findings, the comparison by Stewart et
al. [16] on somatic variants at the RNA and DNA level showed 7 of the 130 variants (5%) detected
at only the DNA level within their set of 100 breast cancer specimens. Another trade-off using RNA
is the additional step to generate cDNA, which might induce false positive calls by mistakes of the
reverse transcriptase. Again based on our direct comparison of samples with variants at the RNA and
DNA level, the number of false positives is maximally 3% of the detected variants (RNA-only variants).
Though, besides false positives, these RNA-only variants might actually be RNA-DNA differences for
example caused by RNA-editing [49], or true variants not called at the DNA level.
4. Materials and Methods
4.1. Data
We studied all patients with RNA sequencing data within the ICGC BASIS consortium, of which
the cohort has been described previously [17] and data deposited in the European-Genome Phenome
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Archive (accession code EGAS00001001178). Briefly, for a total of 348 primary breast tumors we
generated duplex-specific nuclease-based RNA sequencing data. Four samples were excluded from
analyses due to potential cross-contamination (see below). We did not apply a threshold on tumor
cell percentage within the specimen for inclusion in this study. Clinicopathological data and the
nuclear somatic mutation catalogue were obtained from the Supplementary Tables as provided by
Nik-Zainal et al. [17]. Expression levels of ESR1, PGR (quantile normalized FPKM, log2 transformed)
were obtained as described previously [50]. A complete dataset on all variables used in our analyses
is provided in Supplementary Materials Table S3. In addition, we used publically available RNA
sequencing data of twelve human tissue specimens obtained via a similar sequencing approach [20],
that has been deposited in NCBI’s Gene Expression Omnibus (GEO) (accession code GSE45326). Also,
we used the mtDNA variants called by Ju et al. [15] from whole-genome or whole-exome sequencing
data of DNA from the primary breast tumor specimens and matched normal tissue specimens as
provided in their Supplementary Tables.
4.2. Bioinformatics
Sequencing reads were aligned using STAR v2.4.2.a [51] against the Genome Reference
Consortium Human Build 38 (GRCh38, GenBank assembly GCA_000001405.15), which contains
as the mitochondrial contig the revised Cambridge Reference Sequence (rCRS). Only non-duplicated
uniquely mapped reads on mtDNA were used for further analysis, to avoid the potential use of
improper assigned nuclear insertions of mitochondrial origin (NUMTs, mitochondrial pseudogenes).
Note that RNA expression of NUMTs has been shown to be absent or negligibly low [11,43]. Total
read depth was estimated based on the read length (75 nucleotides) and mtDNA size (16,569
nucleotides). FeatureCounts v 1.4.6 [52] was used to count mapped reads using mtDNA as
the meta-feature and each genomic region (13 mRNAs, 22 tRNAs, 2 rRNAs) as the features,
allowing multi-overlapping reads (-O) because of the polycistronic nature of mitochondrial RNA
transcripts. We normalized read counts to transcripts per million (TPM) for the entire mitochondrial
contig (mtDNA read counts versus total read counts assigned to genes in GRCh38, defined as
entire mtDNA levels) and for each mitochondrial-encoded gene (gene read counts versus total
mtDNA read counts, defined as <gene> levels). In this way, the TPM for the entire mtDNA
represents the total amount of mtRNA influenced by both mtDNA content, transcription rate
and transcript stability, whereas the TPM for each mitochondrial-encoded gene represents the
variation in gene expression driven by processing of the polycistronic transcripts and transcript
stability [53]. A complete dataset of all expression levels is provided in Supplementary Materials
Table S4. Variants alternative to rCRS were called using GATK HaplotypeCaller 3.4-46-gbc02625 [54]
using default settings (including downsampling_type = BY_SAMPLE, downsample_to_coverage =
500, standard_min_confidence_ threshold_for_calling = 20). In this way, maximum depth of coverage
is controlled at each locus, resulting in a more even coverage of variants between the samples.
Hard-filtering was applied to the called variants for quality by depth (QD > 2), alternative depth
(AD of ALT > 10) and strand odds ratio (variants with allele frequency ≤ 95% i.e., heteroplasmic
variants: SOD < 4 for SNVs and SOD < 10 for INDELs; variants with allele frequency > 95% i.e.,
(near) homoplasmic: no filtering). In this way, the allele frequency of detected variants was high and
confident enough to be a true variant and likely no sequencing errors or PCR mistakes. In addition,
after visual inspection of variants (Integrative Genomics Viewer [55,56]), potential false positive calls in
challenging regions were excluded: positions surrounding the homopolymer region 301–315 (“D310”),
positions 512–513 due to a repetitive sequence, alternative C calls at positions 16,182–16,183 and 16,189
due to polyC sequences, and alternative A at positions 4264, 5513 and 12,138–12,139 due to polyA
sequences. A complete dataset of all remaining variants is provided in Supplementary Materials
Table S5. All remaining single nucleotide variants were used in a nucleotide BLAST against the
human reference sequence (NCBI’s nucleotide web blast, https://blast.ncbi.nlm.nih.gov) with the
surrounding reference sequence (30 bases 5′ and 30 bases 3′) to uncover potential NUMT events, but
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none were recovered. The conservation index (45 species conservation) for the protein-coding genes,
tRNAs and rRNAs were obtained via SNV Query in Mitomaster [57]. The haplotype of each case
was estimated by using the heteroplasmic and homoplasmic variants in HaploGrep v2 [58]. Sample
cross-contamination was estimated using only the heteroplasmic variants (allele frequency ≤ 95%)
in haplotype assignment. This identified four samples with heteroplasmic contamination of another
haplotype, therefore these samples were excluded from analyses. Sample mismatch between cases with
variants called in both RNA (our dataset) and DNA (dataset Ju et al. [15]) sequencing data (n = 168)
was estimated by haplotyping based on all near-homoplasmic variants (allele frequency > 95%), and
comparison of the obtained haplogroup. Mismatch was observed for 13 patients, but after manual
inspection specificity could be confirmed for 10 patients by the presence of private variants. Two
patients with a clear mismatch, and one patient ambiguous in mismatch, were excluded from the
RNA-DNA comparison analyses (n = 165 remaining).
4.3. Statistics
Performed statistical tests are reported in the results section. All statistical tests were two-sided,
and P values smaller than 0.05 were considered as statistically significant. Outliers data points in
boxplots are defined as Q1−1.5*IQR or Q3+1.5*IQR. Analyses were performed in R version 3.3.2
(https://cran.r-project.org). Data analyses included usage of the following packages: the set of
tidyverse, ggcorplot, SomaticSignatures [59] and VennDiagram [60].
5. Conclusions
To conclude, in this explorative study on the role of mtRNA in breast cancer, we found that
somatic variants at the DNA level are reflected at the RNA level with no hotspot mutations and great
heterogeneity across tumors. We confirm that the number of somatic variants within the mitochondrial
transcriptome is not associated with the mutational processes shaping the nuclear genome but instead,
is associated with age of diagnosis. Furthermore, we show that mitochondrial expression is related to
ER status. The exact consequence of the observed differences in mtRNA expression and the detected
somatic variants on cancer metabolism and clinical outcome warrants further study.
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Appendix A
Appendix A.1. Comparison of Mitochondrial Variants at the RNA and DNA Level
By using the dataset published by Ju et al. [15] concerning somatic mitochondrial variants in
tumor and matched normal specimens at the DNA level, we intended to compare mitochondrial
variants called in primary breast tumor tissue specimens at the RNA and the DNA level. Their dataset
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includes a total of n = 381 breast tumor specimens, of which n = 165 cases are overlapping with
our dataset.
The DNA dataset contains 8892 single nucleotide variants (SNVs) on 1744 positions within the
381 cases (Figure A1), of which 589 variants classified as somatic (using VarScan2, see Ju et al. [15]).
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The variant allele frequency of these somatic variants was distributed with a peak at the lower
end of allele frequencies (Figure A2). The detected somatic variants were distributed along the entire
mitochondrial genome (Figure A1), with 50 (8.5%) variants located n the tRNA genes, 103 (17.5%)
in rRNA genes, 80 (13.6%) n the D-loop, 6 (1.0%) in the non-coding r gions, and 350 (59.4%) in he
RNA genes of which 285 (81.4%) had a nonsynonymous effect on the coding amino acid (Figure A3).
Relative to their genomic size (9.0% tRNA genes, 15.1% rRNA ge es, 6.8% D-loop, 0.4% non-coding,
68.7% mRNA genes) more variants were present i the D-loop and fewer in the mRNA genes sher
exact p < 0.001). Also compared to the germline variants, there is a difference in genomic distribution:
fewer somatic variants in the D-loop but more in the tRNA and mRNA genes, and an enrichment for
somatic nonsynonymous mRNA variants (Fisher exact p < 0.001) (Figure A3). The positions of somatic
variants were much more conserved among species compared to the germline variants (Mann-Whitney
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test p < 0.001), as measured by the fraction of species that harbor the reference sequence at that position
(Conservation Index of respectively median (IQR) 0.96 (0.36) and 0.76 (0.69)).
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A total of 74 (12.6%) somatic variants were recurrent and positioned on 34 mitochondrial positions.
Also, majority of the somatic variants (89.5%) represented the typical replication-coupled mtDNA
substitution pattern with predominantly C > T and T > C transitions in a nucleotid context similar to
the germline variants (Figure A4). Compared to the detecte germline variant the ratio be w en C > T
and T > C variants s shifted (Fisher exact p < 0.001) with an increased number of C > T transitions
among the somatic variants (Figure A4). In the cohort, there are 101 (26%) cases with 0 somatic variants,
117 (31%) with 1 somatic variant, and 163 (43%) with more than 1 somatic variant (range 2 to 7). Of
the cases with more than 1 somatic variant, 103 (63%) had a difference >20% allele frequency between
variants, indicative for (sub-)clonality.
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When comparing these findings at the DNA level with our findings at the RNA level, no
differences were observed in genomic distribution of the somatic variants (Fisher’s exact p = 0.1), the
conservation index of somatic variants (Mann-Whitney test p = 0.4), and the recurrence rate (Fisher’s
exact p = 0.3). However, the substitutional pattern differed, with a higher fraction of C > A substitutions
at the DNA level (4.8%) compared to the RNA level (1.1%) (Fisher’s exact p < 0.001).
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Appendix A.2. Direct Comparison of Mitochondrial Variants at the RNA and DNA Level of Overlapping Cases
We next focused on the variants called within the overlapping cases within our RNA and the
published DNA dataset (n = 165 cases). As stated in the main manuscript text, of the variants detected
at both the RNA and DNA level only a few (n = 10, 0.3%) had a discrepancy in classification as either
‘somatic’ or ‘germline’ (resp. n = 4 and n = 6, Table A1). These were misclassifications at the RNA
level, mainly due to the absence of information on the matched normal tissue: variants misclassified
as ‘germline’ at the RNA level had allele frequencies > 95%, indicative for germline origin, but were
not detected in the matched normal DNA whereas they were present in the matched tumor DNA and
thus of somatic origin. Also, variants misclassified as ‘somatic’ at the RNA level had allele frequencies
between 85% and 95% allele frequency, but were detected in the matched normal DNA as well as the
matched tumor DNA and thus of germline origin. Also, of the variants detected at both the RNA and
DNA level, only a few variants (n = 7, 0.2%) showed a strong deviation in variant frequency (>30%
difference) (n = 3 germline and n = 4 somatic) (Table A2). In contrast to previous observations that
mainly variants in tRNAs have allelic imbalances [9], none of them occurred at tRNA sites.
We continued evaluating the variants called within the overlapping cases present at either only
the DNA or only the RNA level. A total of 120 variants (3.0%) were only called at the DNA level
(103 somatic and 17 germline) (Table A2) and 108 variants (2.7%) were present at only the RNA level
(47 somatic and 61 germline) (Table A3). Within the aligned reads of the RNA data (BAM file) we
inspected if variants called at the DNA-only level were truly not present at the RNA level or just not
called (Table A2). Majority of the called DNA variants were present in the RNA alignment data but not
called by our used algorithm (n = 108, 90%), a few variants were not (sufficiently) covered (n = 5, 4%),
and some were sufficiently covered but truly not present as alternative allele (n = 7, 6%). Unfortunately,
we were unable to visually inspect variants in the DNA alignment data (not available) and thus the
relevance of variants present at only the RNA level was not evaluable. Interestingly, when evaluating
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the substitution pattern of variants detected at both the RNA and DNA level (Figure A5), and at either
the RNA or DNA level, the higher fraction of C > A substitutions at the DNA level compared to the
RNA level appeared mainly due to variants called at only the DNA level.
Given these results, the differences we observe in called variants at the RNA and DNA level is
likely an effect of differences in either the expression at the RNA level (biological) the calling algorithms
used (technical).
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Table A1. Positions misclassified at RNA versus DNA.
Sample Variant Depth RNATumor
VAF RNA









P_6042a r.199u>c 1953 99.3% Germline g.199T>C 6585 67.1% 208 0.5% Somatic
P_9571a r.1010a>c 1655 97.1% Germline g.1010A>C 21,840 94.9% 763 0.0% Somatic
P_6409a r.4344u>c 146 97.9% Germline g.4344T>C 16,068 68.9% 1707 0.1% Somatic
P_6043a r.5353g>a 1099 97.6% Germline g.5353G>A 20,514 88.0% 544 0.0% Somatic
P_5956a r.11453g>a 1655 96.6% Germline g.11453G>A 21,214 96.3% 4230 0.0% Somatic
P_9568a r.14841a>g 1877 97.4% Germline g.14841A>G 12,060 86.5% 806 0.1% Somatic
P_4982a r.94g>a 698 91.1% Somatic g.94G>A 9643 99.8% 1449 99.5% Germline
P_4982a r.152u>c 614 93.0% Somatic g.152T>C 11,738 99.8% 2090 99.0% Germline
P_8622a r.497c>u 39 84.6% Somatic g.497C>T 11,020 99.8% 1975 99.5% Germline
P_4963a r.16302a>g 708 94.7% Somatic g.16302A>G 7042 97.3% 7860 86.6% Germline
Table A2. Variants called at only the mtDNA level.











P_6719a g.2A>T Control-Region 81 4.94 59 0 15 0.00 na
P_6409a g.66G>T Control-Region 1712 3.27 465 0 644 0.16 na
P_9569a g.73A>G Control-Region 6118 11.43 146 0 1010 11.58 Yes
P_6719a g.185G>A Control-Region 3193 99.72 3421 99.18 10 100.00 Yes
P_9592a g.195T>C Control-Region 7012 4.04 2672 0.04 1076 3.35 Yes
P_4977a g.263A>G Control-Region 10,036 100 2142 99.91 9 100.00 Yes
P_9597a g.293T>C Control-Region 2568 12.27 810 0 1503 7.25 Yes
P_4847a g.307C>A Control-Region 1275 22.98 2124 0.09 228 0.00 No
P_4958a g.316G>A Control-Region 3513 10.65 698 2.72 376 3.99 Yes
P_5947a g.319T>C Control-Region 2942 4.11 1185 0.25 1015 26.21 Yes
P_5947a g.321T>C Control-Region 3184 4.74 1227 0.08 1017 26.16 Yes
P_4847a g.346T>C Control-Region 1557 31.34 2300 0.04 304 37.17 Yes
P_4847a g.347G>A Control-Region 1492 31.37 2030 0.05 305 35.08 Yes
P_11340a g.456C>T Control-Region 8351 99.8 462 99.78 7 100.00 Yes
P_9571a g.462C>T Control-Region 17,653 99.93 584 99.83 0 - Yes
P_6719a g.462C>T Control-Region 5300 99.87 5718 99.88 4 100.00 Yes
P_4069a g.462C>T Control-Region 9108 99.89 1760 100 21 95.24 Yes
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P_9571a g.489T>C Control-Region 18,133 99.98 619 100 2 100.00 Yes
P_6719a g.489T>C Control-Region 5798 99.91 5977 99.97 4 100.00 Yes
P_4069a g.489T>C Control-Region 9408 99.97 1766 100 18 100.00 Yes
P_6422a g.549C>T Control-Region 15,224 99.76 9454 99.27 15 93.33 Yes
P_5928a g.730A>T MT-RNR1 12,334 12.93 395 0 5056 4.94 Yes
P_11389a g.903T>C MT-RNR1 11,568 4.76 1006 0 5053 0.26 Yes
P_6413a g.1284T>C MT-RNR1 8416 25.5 2589 0.04 5030 1.83 Yes
P_11399a g.1320G>A MT-RNR1 6173 4.47 1995 0 5039 0.02 No*
P_4845a g.1464G>A MT-RNR1 6496 12.96 7902 0.19 5018 6.50 Yes
P_6719a g.1748G>A MT-RNR2 10,396 25.31 9000 0.06 4674 10.68 Yes
P_9754a g.1758T>C MT-RNR2 10,021 3.42 2541 0.04 5035 1.81 Yes
P_8618a g.1906G>C MT-RNR2 8094 3.43 5953 0.03 5038 0.02 No*
P_11384a g.1913G>A MT-RNR2 8494 4.07 2090 0.05 5031 0.58 Yes
P_9592a g.1939G>A MT-RNR2 16,324 3.59 6432 0.06 5022 2.59 Yes
P_6413a g.1987G>A MT-RNR2 8817 11.47 2498 0.04 4972 1.57 Yes
P_11380a g.2024C>T MT-RNR2 12,996 14.06 647 0 5024 2.31 Yes
P_11377a g.2343G>A MT-RNR2 7852 3.48 1118 0 5049 0.04 No*
P_9572a g.2492G>A MT-RNR2 13,639 3.43 671 0.15 5049 5.27 Yes
P_7221a g.2571G>A MT-RNR2 8410 3.22 2488 0.08 5007 3.40 Yes
P_11374a g.2695G>A MT-RNR2 4771 3.98 1416 0 5045 0.71 Yes
P_4976a g.2716G>A MT-RNR2 21,489 7.3 18,243 0.06 4996 4.06 Yes
P_5950a g.3065T>C MT-RNR2 7371 5.24 1548 0 4870 3.72 Yes
P_8980a g.3068G>A MT-RNR2 15,125 12.65 3374 0.12 4997 4.16 Yes
P_9573a g.3097T>C MT-RNR2 10,249 9.23 592 0.17 5036 5.90 Yes
P_7215a g.3617T>C MT-ND1 12,614 3.24 2196 0 1400 4.07 Yes
P_11375a g.3715G>C MT-ND1 9098 3.7 339 0.59 4889 1.82 Yes
P_4080a g.4153G>A MT-ND1 14,450 7.7 2259 0.04 53 3.77 Yes
P_6411a g.4308G>A MT-TI 13,780 3.72 1097 0 738 6.91 Yes
P_7218a g.4336T>C MT-TQ 11,432 99.9 2181 100 3 66.67 Yes
P_8979a g.4399T>C MT-TQ 7338 20.37 1572 0 29 20.69 Yes
P_4833a g.4412G>A MT-TM 10,532 5.86 4078 0.02 1039 87.20 Yes
P_4072a g.4429G>A MT-TM 16,360 55.94 2245 0.04 548 85.22 Yes
P_9777a g.4582T>C MT-ND2 3336 17.99 2439 0 19 0.00 na
P_11819a g.4924G>A MT-ND2 7357 9.11 4036 0.05 3760 6.97 Yes
P_4080a g.5581A>G Non-Coding 17,806 99.66 2669 99.96 0 - Yes
P_6728a g.5582A>G Non-Coding 13,659 99.34 11,657 99.91 9 100.00 Yes
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P_4982a g.5703G>A MT-TN 13,401 91.4 2276 0.04 1963 89.61 Yes
P_4971a g.5920G>A MT-CO1 6202 3.58 1517 0.07 4376 7.24 Yes
P_11340a g.6255G>A MT-CO1 11,906 6.16 824 0 1638 9.77 Yes
P_6422a g.6673T>C MT-CO1 20,090 4.39 12,278 0.02 1080 5.28 Yes
P_9574a g.6724T>C MT-CO1 10,549 6.03 871 0 5018 6.10 Yes
P_9574a g.7191T>C MT-CO1 11,204 6.12 932 0.11 5024 5.77 Yes
P_11377a g.7207G>A MT-CO1 8421 5.85 1093 0 5036 2.76 Yes
P_7214a g.7219G>A MT-CO1 11,168 3.36 2565 0 4983 3.45 Yes
P_4080a g.7595G>A MT-CO2 17,880 20.37 2789 0.07 3 0.00 na
P_7219a g.7652T>C MT-CO2 9000 7.7 2654 0.04 4787 7.65 Yes
P_11336a g.7935T>C MT-CO2 9586 5.42 594 0.34 4985 7.36 Yes
P_9592a g.8213G>A MT-CO2 15,889 3.63 6009 0.02 4964 3.28 Yes
P_4967a g.8249G>A MT-CO2 13,941 3.21 7740 0.03 5031 0.85 Yes
P_9572a g.8269G>C MT-CO2 6539 3.17 404 1.24 4858 0.00 No
P_11372a g.8270C>T Non-Coding 1447 98.48 184 96.2 4755 99.75 Yes
P_9002a g.8278C>G Non-Coding 2694 15.55 75 6.67 3092 0.00 No
P_9572a g.8290G>C Non-Coding 6059 5.73 370 2.43 96 1.04 na
P_9572a g.8291A>C Non-Coding 6217 4.68 382 2.36 93 5.38 Yes
P_3989a g.8448T>C MT-ATP8 11,980 8.68 5300 0.02 5042 1.23 Yes
P_7214a g.8547T>C MT-ATP8/6 7924 3.14 1835 0.05 3949 0.20 Yes
P_4977a g.8860A>G MT-ATP6 13,075 99.99 3626 99.97 46 97.83 Yes
P_9754a g.9053G>A MT-ATP6 10,819 4.92 2532 0 5011 3.47 Yes
P_9001a g.9078T>C MT-ATP6 14,729 5.89 497 0.2 2045 3.03 Yes
P_4958a g.9181A>G MT-ATP6 9010 39.35 2221 0 4870 49.96 Yes
P_5936a g.9285A>T MT-CO3 6732 11.51 3408 0.03 4916 6.96 Yes
P_6413a g.9286T>C MT-CO3 6771 11.79 1989 0.2 4904 5.69 Yes
P_11337a g.9429G>A MT-CO3 16,236 3.47 404 0 4975 3.50 Yes
P_5960a g.9497T>C MT-CO3 10,947 3.27 2603 0 4961 2.80 Yes
P_11336a g.9594C>T MT-CO3 10,659 5.65 623 0.16 4845 5.49 Yes
P_9567a g.9645G>A MT-CO3 11,647 6.36 700 0.14 5021 3.94 Yes
P_9847a g.10177G>A MT-ND3 22,790 3.05 18,685 0.02 3403 7.35 Yes
P_7426a g.10463T>C MT-TR 9817 99.98 1300 99.92 7 100.00 Yes
P_9757a g.10747T>C MT-ND4L 6998 7.82 2229 0.04 4963 10.50 Yes
P_11336a g.10838A>G MT-ND4 10,950 9.52 617 0 5006 5.81 Yes
P_5936a g.11195G>A MT-ND4 7126 8.73 3615 0.03 4923 7.39 Yes
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P_9582a g.11477G>A MT-ND4 11,726 3.77 12,886 0.02 4963 5.00 Yes
P_7206a g.11825G>A MT-ND4 12,293 3.54 1094 0.09 4999 5.82 Yes
P_4266a g.11984T>C MT-ND4 14,006 13.17 8778 0.03 4951 9.41 Yes
P_9755a g.12154C>T MT-TH 8116 3.7 1603 0.06 263 8.75 Yes
P_7221a g.12618G>A MT-ND5 9056 6.1 2555 0.04 2853 8.24 Yes
P_8981a g.12769G>A MT-ND5 10,621 7.06 3108 0.03 4976 8.16 Yes
P_5930a g.12771G>A MT-ND5 10,265 11.83 3150 0 4972 9.61 Yes
P_6413a g.12977T>C MT-ND5 7340 34.1 2123 0.09 4942 2.47 Yes
P_4847a g.13099G>A MT-ND5 13,805 5.16 4972 0.02 4931 1.60 Yes
P_7409a g.13156C>T MT-ND5 8790 4.55 2599 0.04 4891 7.56 Yes
P_5946a g.13178G>A MT-ND5 5740 8.89 2846 0.07 3483 11.08 Yes
P_8979a g.13198G>A MT-ND5 11,789 8.59 2741 0 2877 7.92 Yes
P_11336a g.13272C>A MT-ND5 9660 5.48 579 0 4603 2.00 Yes
P_8979a g.13496C>A MT-ND5 10,985 5.5 2332 0.04 3916 5.80 Yes
P_11374a g.13531G>A MT-ND5 4731 5.14 1252 0 5007 3.87 Yes
P_11391a g.13567A>G MT-ND5 1322 23.83 856 0 5009 0.86 Yes
P_11372a g.14112C>A MT-ND5 8553 10.1 1251 0.08 4959 10.71 Yes
P_8611a g.14197T>C MT-ND6 10,577 5.01 4713 0.04 5005 5.97 Yes
P_7215a g.14447T>C MT-ND6 13,776 3.47 2242 0 2321 2.76 Yes
P_11374a g.14760G>A MT-CYB 5961 19.28 1421 0.07 921 0.00 No
P_4959a g.14788T>C MT-CYB 13,250 10.17 8208 0.12 4608 6.45 Yes
P_9570a g.14888G>A MT-CYB 15,466 3.84 517 0 3649 5.10 Yes
P_5954a g.14939T>C MT-CYB 8033 3.39 2633 0.04 2959 6.69 Yes
P_4982a g.15012T>C MT-CYB 22,666 8.39 4348 0.05 5016 7.93 Yes
P_5950a g.15093G>A MT-CYB 8082 5.26 1601 0 5037 7.72 Yes
P_9582a g.15170G>A MT-CYB 11,759 3.46 13,082 0.02 3899 9.69 Yes
P_11342a g.15242G>A MT-CYB 11,745 3.32 373 0 4339 6.04 Yes
P_9582a g.15854T>C MT-CYB 10,545 6.89 12,711 0.06 3895 7.01 Yes
P_4977a g.15970T>C MT-TP 19,783 99.96 5232 100 3 100.00 Yes
P_4847a g.16033G>A Control-Region 14,332 7.59 5556 0.02 2732 0.48 Yes
P_7433a g.16147C>T Control-Region 15,174 11 3874 0.03 2873 1.98 Yes
P_9539a g.16293A>G Control-Region 2683 9.58 470 0.21 3315 9.20 Yes
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P_4982a r.72u>c Control-Region Somatic 318 20.44 True variant (mutually exclusive 73G, 94T)
P_6406a r.72u>c Control-Region Germline 1906 99.79 True variant
P_9589a r.73a>g Control-Region Germline 592 99.83 True variant
P_5959a r.73a>g Control-Region Germline 954 100.00 True variant
P_11394a r.73a>g Control-Region Germline 923 100.00 True variant
P_11389a r.146u>c Control-Region Germline 694 99.71 True variant
P_8978a r.146u>c Control-Region Germline 371 99.73 True variant (phased with 185A and 204C)
P_8611a r.146u>c Control-Region Germline 1599 99.75 True variant (phased with 195C)
P_8981a r.146u>c Control-Region Germline 308 100.00 True variant
P_8609a r.152u>c Control-Region Somatic 1448 69.96 True variant (phased with 195C)
P_10014a r.152u>c Control-Region Germline 2272 95.38 True variant
P_4606a r.152u>c Control-Region Germline 98 98.98 True variant
P_4266a r.152u>c Control-Region Germline 956 99.37 True variant
P_8618a r.152u>c Control-Region Germline 437 99.77 True variant
P_8979a r.152u>c Control-Region Germline 371 100.00 True variant
P_4261a r.182c>u Control-Region Somatic 1220 77.54 True variant
P_11383a r.185g>a Control-Region Germline 301 99.67 True variant (phased with 150T and 228A)
P_5928a r.185g>a Control-Region Germline 723 100.00 True variant (phased with 188G and 228A)
P_9592a r.188a>g Control-Region Germline 814 99.63 True variant (phased with 185A and 228A)
P_5928a r.188a>g Control-Region Germline 716 100.00 True variant (phased with 185A and 228A)
P_5956a r.188a>g Control-Region Germline 1450 100.00 True variant (phased with 185A and 228A)
P_9571a r.188a>g Control-Region Germline 37 100.00 True variant (phased with 185A, 222T and 228A)
P_4069a r.189a>g Control-Region Germline 997 100.00 True variant
P_11372a r.195u>c Control-Region Germline 715 99.72 True variant (phased with 152C and 263G)
P_8978a r.228g>a Control-Region Somatic 573 82.72 True variant (phased with 185A, 204C, 263G)
P_11383a r.228g>a Control-Region Germline 585 99.83 True variant (phased with 185A, 263G, 295T)
P_9597a r.263a>g Control-Region Germline 2341 99.83 True variant (phased with 228A and 295T)
P_10010a r.263a>g Control-Region Germline 1331 99.85 True variant
P_7238a r.263a>g Control-Region Germline 1388 99.86 True variant (phased with 295T)
P_8611a r.263a>g Control-Region Germline 1948 99.95 True variant (phased with 195C)
P_8830a r.263a>g Control-Region Germline 892 100.00 True variant (phased with 207A and 234G)
P_7238a r.295c>u Control-Region Germline 766 99.48 True variant (phased with 263G)
P_5956a r.295c>u Control-Region Germline 1121 99.91 True variant (phased with 263G)
P_6732a r.295c>u Control-Region Germline 545 100.00 True variant
P_9597a r.295c>u Control-Region Germline 1272 100.00 True variant (phased with 228A and 263G)
P_7316a r.456c>u Control-Region Germline 88 95.45 True variant
P_9758a r.1604g>a MT-TV Somatic 159 23.27 True variant
P_11399a r.1669g>a MT-TV Somatic 534 41.20 True variant
P_6730a r.1973g>a MT-RNR2 Somatic 1171 57.05 True variant
P_4977a r.2166c>u MT-RNR2 Somatic 1433 18.42 Potential artefact; at start of read ACCxATA context
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P_10010a r.2300g>a MT-RNR2 Somatic 2066 13.84 True variant (in DNA! 2300G>A, 9106|5497|37.64%)
P_7431a r.2416u>c MT-RNR2 Somatic 855 84.80 True variant
P_6406a r.3109u>c MT-RNR2 Somatic 1407 38.38 True variant
P_4963a r.3283g>a MT-TL1 Somatic 908 29.52 True variant
P_4606a r.3535u>c MT-ND1 Somatic 2203 92.74 True variant
P_4080a r.3705g>a MT-ND1 Somatic 51 94.12 True variant
P_5942a r.3796a>g MT-ND1 Germline 2032 98.43 True variant
P_9754a r.3913g>a MT-ND1 Somatic 1685 12.11 True variant
P_7219a r.4282g>a MT-TI Somatic 76 35.53 True variant
P_6733a r.4360g>a MT-TQ Somatic 54 40.74 True variant
P_6728a r.4408g>a MT-TM Somatic 199 17.09 True variant
P_6043a r.4986a>g MT-ND2 Somatic 2073 39.22 True variant
P_4847a r.5479u>c MT-ND2 Somatic 890 13.03 Potential artefact; at end of read TCCxACC context
P_9567a r.6569c>u MT-CO1 Somatic 1773 88.72 True variant
P_4970a r.7045u>c MT-CO1 Somatic 761 12.22 True variant
P_9847a r.7146a>g MT-CO1 Germline 757 98.15 True variant
P_9757a r.7579u>c MT-TD Somatic 109 16.51 True variant
P_11383a r.7698u>c MT-CO2 Somatic 2277 12.60 True variant
P_9541a r.7765a>g MT-CO2 Somatic 797 17.69 True variant
P_4976a r.7895u>c MT-CO2 Somatic 2368 28.08 True variant
P_11819a r.8149a>g MT-CO2 Somatic 660 92.58 True variant
P_7216a r.8286u>c Non-Coding Somatic 364 49.73 True variant
P_8978a r.8408c>u MT-ATP8 Germline 2239 99.60 True variant
P_4604a r.9989u>c MT-CO3 Germline 302 98.68 True variant
P_4833a r.10306a>c MT-ND3 Somatic 1004 35.26 True variant
P_4976a r.11718g>a MT-ND4 Somatic 1304 92.33 True variant
P_6722a r.11899u>c MT-ND4 Germline 691 95.37 True variant (phased with 11914A)
P_8978a r.12763g>a MT-ND5 Somatic 1602 89.20 True variant
P_9754a r.12876c>u MT-ND5 Germline 1478 97.29 True variant
P_6411a r.13528a>g MT-ND5 Somatic 1701 91.59 True variant
P_4983a r.13552g>a MT-ND5 Somatic 1569 91.65 True variant
P_9002a r.14389c>u MT-ND6 Somatic 1718 93.95 True variant
P_5930a r.14721g>c MT-TE Somatic 302 27.81 True variant (phased with 14766T)
P_8978a r.15495u>c MT-CYB Somatic 1812 94.09 True variant
P_11337a r.15607a>g MT-CYB Germline 959 99.06 True variant
P_4982a r.15904c>u MT-TT Somatic 344 34.01 True variant (overlapping 15927A)
P_4982a r.15927g>a MT-TT Somatic 344 36.92 True variant (overlapping with 15904)
P_4847a r.16092u>c Control-Region Germline 1838 99.78 True variant
P_11389a r.16093u>c Control-Region Somatic 745 12.62 True variant
P_9582a r.16093u>c Control-Region Somatic 753 12.88 True variant (phased with 16126C)
P_4072a r.16093u>c Control-Region Germline 1041 27.76 True variant
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P_9567a r.16093u>c Control-Region Somatic 2459 92.19 True variant
P_4955a r.16093u>c Control-Region Germline 1298 98.69 True variant
P_4970a r.16104c>u Control-Region Germline 800 81.88 True variant
P_8979a r.16184c>u Control-Region Germline 317 100.00 True variant
P_4606a r.16186c>u Control-Region Germline 181 96.69 True variant
P_8830a r.16209u>c Control-Region Germline 863 100.00 True variant (phased with 16171A, 16183C, 16188C, 16233T, 16258T)
P_8830a r.16223c>u Control-Region Germline 1197 100.00 True variant (phased with 16171A, 16183C, 16188C, 1609C, 16258T)
P_9002a r.16235a>g Control-Region Germline 1409 82.82 True variant (phased with 16183C, 16184A, 16189C, 16217C)
P_11338a r.16235a>g Control-Region Somatic 2188 93.01 True variant (phased with 16293G and 16304C)
P_6730a r.16267c>u Control-Region Somatic 2167 34.98 True variant
P_6732a r.16278c>u Control-Region Somatic 2661 47.35 True variant
P_9575a r.16290c>u Control-Region Somatic 1530 25.16 True variant (phased with 16265C, 16291T, 16335G)
P_11341a r.16293a>g Control-Region Germline 1205 100.00 True variant (phased with 16331C, 16354T)
P_9582a r.16294c>u Control-Region Germline 870 99.89 True variant (phased with 16304C)
P_9847a r.16294c>u Control-Region Germline 731 100.00 True variant (phased with 16278T, 16293G, 16311C, 16360T)
P_9582a r.16304u>c Control-Region Germline 663 99.85 True variant (phased with 16294T)
P_9596a r.16311u>c Control-Region Germline 802 98.63 True variant
P_5956a r.16311u>c Control-Region Germline 757 100.00 True variant
P_9761a r.16336g>a Control-Region Germline 1571 100.00 True variant
P_9541a r.16342u>c Control-Region Germline 806 99.75 True variant
P_11381a r.16356u>c Control-Region Germline 1466 99.86 True variant
P_9568a r.16362u>c Control-Region Germline 1232 99.84 True variant (phased with 16304C)
P_5946a r.16362u>c Control-Region Germline 327 100.00 True variant
P_9599a r.16362u>c Control-Region Germline 376 100.00 True variant (phased with 16325C)
P_11819a r.16362u>c Control-Region Germline 373 100.00 True variant
P_10010a r.16519u>c Control-Region Somatic 732 56.15 True variant
P_6730a r.16540c>u Control-Region Somatic 1142 61.56 True variant (phased with 16519C)
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